Vertex Pharmaceuticals
NEWS
It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
Although some clinical trials are being slowed or halted, others are reporting out data. Here’s a look.
The $500,000 gift was in response to the COVID-19 outbreak and a need for more support, testing capacity and advancements.
The U.S. Food and Drug Administration has two PDUFA dates this week, one for a type of epilepsy and the other for a triple-combination drug for cystic fibrosis. Here’s a look.
The most recent BioSpace Ideal Employer Report revealed the impact of team dynamics on employees within life sciences organizations.
The BioSpace Ideal Employer Report examined aspects regarding the importance of culture within life sciences organizations.
Similar to the Biotech Bay list, BioSpace takes a look at the top 10 2019 Life Sciences Ideal Employer Report’s for Genetown.
As usual, it was a busy week for clinical trial updates. Here’s a look.
CRISPR Therapeutics and Vertex Pharmaceuticals announced positive interim data from the first two patients in the companies’ ongoing Phase I/II clinical trials of its CRISPR/Cas9 gene-editing therapy CTX001.
JOBS
IN THE PRESS